ISSN 1662-4009 (online)

Previous issue | Volume 21 | ESPEYB21

Yearbook of Paediatric Endocrinology 2024

ey0021.5-7 | Novel Treatments | ESPEYB21

5.7. Burosumab vs conventional therapy in children with x-linked hypophosphatemia: results of the open-label, phase 3 extension period

Ward Leanne M. , Hogler Wolfgang , Glorieux Francis H. , Portale Anthony A. , Whyte Michael P. , Munns Craig F. , Nilsson Ola , et al.

In brief: This report describes the efficacy and safety of burosumab during the open-label extension period of the original Phase 3 study (weeks 64-88) in 21 children with X-linked hypophosphatemia (XLH) who continued to receive burosumab or crossed over from conventional therapy to burosumab.Commentary: X-linked hypophosphatemia (XLH) is a rare inherited disorder of phosphorus metabolism caused by loss-of-function mutations in the PHEX gene, re...

ey0021.5-8 | Novel Treatments | ESPEYB21

5.8. Management of RANKL-mediated disorders with denosumab in children and adolescents: a global expert guidance document

Vanderniet Joel A. , Szymczuk Vivian , Hogler Wolfgang , Beck-Nielsen Signe S. , Uday Suma , Merchant Nadia , Crane Janet L. , Ward Leanne M. , Boyce Alison M. , Munns Craig F.

In brief: This article reviews the evidence and provides expert opinion on the safe and appropriate use of denosumab in children and adolescents with RANKL-mediated disorders such as giant cell bone tumours, fibrous dysplasia and juvenile Paget’s disease.Commentary: Receptor activator of nuclear factor κB ligand (RANKL) is expressed by osteogenic cells and induces osteoclast differentiation by binding to RANK on osteoclast precursors. Excessive...

ey0021.5-9 | Novel Treatments | ESPEYB21

5.9. Safety and efficacy of denosumab in children with osteogenesis imperfecta-the first prospective comparative study

Liu Jiayi , Lin Xiaoyun , Sun Lei , Zhang Qian , Jiang Yan , Wang Ou , Xing Xiaoping , Xia Weibo , Li Mei

In brief: This 1-year, open-label, randomised controlled trial examined the effects and tolerability of denosumab, compared with zoledronic acid, on bone mineral density (BMD), spinal morphometry, and safety in a large cohort of children (n=84) with osteogenesis imperfecta. Treatment with denosumab increased BMD and improved spinal morphometry in children with OI, but was frequently associated with rebound hypercalcaemia (in 31%). This rebound hypercalcaemia could be alleviate...

ey0021.5-10 | Novel Treatments | ESPEYB21

5.10. Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial

Savarirayan Ravi , Wilcox William R. , Harmatz Paul , Phillips John , Polgreen Lynda E. , Tofts Louise , Ozono Keiichi , et al.

In brief: This multinational, randomised, double-blind, placebo-controlled, Phase 2 study examined the safety and efficacy of vosoritide, a recombinant C-type natriuretic peptide (CNP) analogue, in 75 children with achondroplasia under age 5 years. Mean gain in height Z-score after 52-weeks was 0•25 (95% CI -0•02 to 0•53). The study was sponsored by BioMarin Pharmaceutical.Commentary: Achondroplasia is one of the most common constitutional...

ey0021.5-11 | Novel Treatments | ESPEYB21

5.11. Vosoritide treatment for children with hypochondroplasia: a phase 2 trial

Dauber Andrew , Zhang Anqing , Kanakatti Shankar Roopa , Boucher Kimberly , McCarthy Tara , Shafaei Niusha , Seaforth Raheem , Grace Castro Meryll , Dham Niti , Merchant Nadia

In brief: This single-arm, open-label, single-centre, Phase 2 study in the US examined the safety and efficacy of vosoritide, a recombinant C-type natriuretic peptide (CNP) analogue, in 26 children with hypochondroplasia. Height SDS increased by (mean) 0.36 during the 12-month treatment period versus the observation period. The study was sponsored by BioMarin Pharmaceutical.Commentary: Hypochondroplasia is a rare skeletal dysplasia that manifests mainly ...

ey0021.5-12 | Novel Treatments | ESPEYB21

5.12. Once-weekly transCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-Blind, placebo-controlled, dose-escalation trial

Savarirayan Ravi , Hoernschemeyer Daniel G. , Ljungberg Merete , Zarate Yuri A. , Bacino Carlos A. , Bober Michael B. , Legare Janet M. , et al.

In brief: This multinational, randomised, double-blind, placebo-controlled, dose-escalation Phase 2 study evaluated the safety and efficacy of TransCon CNP (navepegritide), a C-type natriuretic peptide (CNP) analogue designed to allow continuous CNP exposure with once-weekly dosing, in 42 children with achondroplasia aged 2-10 years. The study was sponsored by Ascendis Pharma.Commentary: Achondroplasia is one of the most common constitutional bone disord...

ey0021.5-13 | Novel Treatments | ESPEYB21

5.13. Low-dose infigratinib increases bone growth and corrects growth plate abnormalities in an achondroplasia mouse model

Demuynck Benoit , Flipo Justine , Kaci Nabil , Dambkowski Carl , Paull Morgan , Muslimova Elena , Shah Bhavik P. , Legeai-Mallet Laurence

In brief: This study investigated the effect of infigratinib, a selective and orally bioavailable FGFR1-3 inhibitor, administered at different doses or according to different dosing regimens, on bone growth in a mouse model mimicking achondroplasia (Fgfr3Y367C/+). This study was partially sponsored by a grant from BridgeBio/QED Therapeutics.Commentary: Achondroplasia is one of the most common constitutional bone diseases (> 300,000 affecte...